Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 3125-3131

  Wang, Cong Jun ^a   Guo, De Kai ^a   You, Tian Geng ^a   Shen, Dong Wei ^a   Wang, Chao ^a   Tang, Lin ^a   Wang, Jian ^a   Xu, Rong Hua ^a,b   Zhang, Hui ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Anti estrogen; Estrogen receptor ; Hepatocellular carcinoma; Wnt inhibitory factor 1; catenin

Indexed keywords

BETA CATENIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; FULVESTRANT; MESSENGER RNA; PROLACTIN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WIF1 PROTEIN, HUMAN;

ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DOWN REGULATION; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; HUMAN; IN VITRO STUDY; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; WNT SIGNALING PATHWAY; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HEP G2 CELLS; HUMANS; IN VITRO TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROLACTIN; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84914173914     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2595     Document Type: Article

References (27)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127: S27-S34, 2004.
3. Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127: S5-S16, 2004.
4. Boonyaratanakornkit V and Edwards DP: Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25: 139-153, 2007.
5. Coe JE, Ishak KG and Ross MJ: Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology 11: 570-577, 1990.
6. Giguère V: To ERR in the estrogen pathway. Trends Endocrinol Metab 13: 220-225, 2002.
7. Bunone G, Briand PA, Miksicek R and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183, 1996.
8. Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
9. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R and Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275: 18447-18453, 2000.
10. Liedert A, Wagner L, Seefried L, Ebert R, Jakob F and Ignatius A: Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem Biophys Res Commun 394: 755-759, 2010.
11. Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398, 2008.
12. Grumolato L, Liu G, Mong P, et al: Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 24: 2517-2530, 2010.
13. Ingle JN, Suman VJ, Rowland KM, et al: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24: 1052-1056, 2006.
14. Dang VH, Nguyen TH, Lee GS, Choi KC and Jeung EB: In vitro exposure to xenoestrogens induces growth hormone transcription and release via estrogen receptor-dependent pathways in rat pituitary GH3 cells. Steroids 74: 707-714, 2009.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)]. Method 25: 402-408, 2001.
16. Carlsson G, Gullberg B and Hafström L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105: 20-23, 1983.
17. Boutin JM, Edery M, Shirota M, et al: Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol Endocrinol 3: 1455-1461, 1989.
18. Chamness GC, Costlow ME and McGuire WL: Estrogen receptor in rat liver and its dependence on prolactin. Steroids 26: 363-371, 1975.
19. Yue W, Wang JP, Li Y, et al: Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer 127: 1748-1757, 2010.
20. Fan M, Yan PS, Hartman-Frey C, et al: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966, 2006.
21. Zhai Y, Zhou G, Deng G, et al: Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 130: 2001-2009, 2006.
22. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
23. Ding Z, Qian YB, Zhu LX and Xiong QR: Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. World J Gastroenterol 15: 2595-2601, 2009.
24. Wu D, Wong P, Li W, Vogel CF and Matsumura F: Suppression of WIF-1 through promoter hypermethylation causes accelerated proliferation of the aryl hydrocarbon receptor (AHR) overexpressing MCF10AT1 breast cancer cells. Toxicology 285: 97-103, 2011.
25. van der Lely AJ, Harris AG and Lamberts S: The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: Influence of age and sex. Clin Endocrinol (Oxf) 37: 181-185, 1992.
26. Ohnishi S, Murakami T, Moriyama T, Mitamura K and Imawari M: Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6: 440-443, 1986.
27. Deng Y, Yu B, Cheng Q, et al: Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J Cancer Res Clin Oncol 136: 1161-1167, 2010.